Why the study?
Does intrapericardial instillation of cisplatin improve outcomes and prevent recurrence in patients with malignant pericardial effusion?
Does intrapericardial instillation of cisplatin improve outcomes and prevent recurrence in patients with malignant pericardial effusion?
Intrapericardial instillation of cisplatin is a feasible palliative treatment for malignant pericardial effusion that can achieve complete response without severe local or systemic toxicity.
Answers are grounded in this paper and cite their sources.
May support palliative use in malignant pericardial effusion; leaves open need for controlled trials to confirm benefit.
Six patients (four men and two women) affected by malignant pericardial effusion, as confirmed by cytologic examination, were treated with direct intrapericardial administration of cisplatin. Median age was 36.8 years (range, 18 to 56 years). After insertion of a radiopaque polyurethane catheter (Centracath Vygon, Laboratoires Pharmaceutiques, Vygon-Ecouen, France), fluid was drained and cisplatin (10 mg in 20 ml of normal saline) was instilled over 5 minutes on 5 consecutive days (total cisplatin dose, 50 mg). At the end of the course, the catheter was withdrawn. Courses were repeated every 2 or 3 weeks in case of fluid reaccumulation. The median number of courses was two, with a range of one to three courses. Three patients achieved complete response and all three died of primary disease progression without evidence of pericardial recurrence or stricture. Mild nausea occurred in all patients. No hematologic and renal toxicity and local or infectious complications were observed.
No takes yet. Share an insight, caveat, or question.
Fiorentino et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: